Gary D. Rubin - Aug 31, 2022 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Gary D. Rubin
Stock symbol
BIAF
Transactions as of
Aug 31, 2022
Transactions value $
$1,190,680
Form type
4
Date filed
10/21/2022, 06:50 PM
Previous filing
Oct 21, 2022
Next filing
Jul 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIAF Common Stock Conversion of derivative security $66.7K +15.9K +44.45% $4.20 51.6K Sep 6, 2022 Direct F1, F2, F4
transaction BIAF Common Stock Conversion of derivative security $1.12M +267K +32.7% $4.20 1.08M Sep 6, 2022 By Trust F1, F3, F5
transaction BIAF Common Stock Conversion of derivative security $161K +38.3K +3.54% $4.20 1.12M Sep 6, 2022 By Trust F1, F3, F6
transaction BIAF Common Stock Conversion of derivative security $394K +93.8K +8.37% $4.20 1.21M Sep 6, 2022 By Trust F1, F3, F7
transaction BIAF Common Stock Conversion of derivative security $269K +64K +5.26% $4.20 1.28M Sep 6, 2022 By Trust F1, F3, F8
transaction BIAF Common Stock Conversion of derivative security $246K +58.6K +4.58% $4.20 1.34M Sep 6, 2022 By Trust F1, F3, F9
transaction BIAF Common Stock Conversion of derivative security $1.19M +230K +17.22% $5.17 1.57M Sep 6, 2022 By Trust F1, F3, F10
transaction BIAF Common Stock Purchase +16.3K +1.04% 1.58M Aug 31, 2022 By Trust F1, F3, F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIAF Secured Convertible Promissory Note Conversion of derivative security -$66.7K 0 Sep 6, 2022 Common Stock 15.9K $4.20 Direct F1, F4
transaction BIAF Secured Convertible Promissory Note Conversion of derivative security -$1.12M 0 Sep 6, 2022 Common Stock 267K $4.20 By Trust F1, F3, F5
transaction BIAF Secured Convertible Promissory Note Conversion of derivative security -$161K 0 Sep 6, 2022 Common Stock 38.3K $4.20 By Trust F1, F3, F6
transaction BIAF Secured Convertible Promissory Note Conversion of derivative security -$394K 0 Sep 6, 2022 Common Stock 93.8K $4.20 By Trust F1, F3, F7
transaction BIAF Secured Convertible Promissory Note Conversion of derivative security -$269K 0 Sep 6, 2022 Common Stock 64K $4.20 By Trust F1, F3, F8
transaction BIAF Secured Convertible Promissory Note Conversion of derivative security -$246K 0 Sep 6, 2022 Common Stock 58.6K $4.20 By Trust F1, F3, F9
transaction BIAF Series A Convertible Preferred Stock Conversion of derivative security $0 -1.61M -100% $0.00* 0 Sep 6, 2022 Common Stock 230K $5.17 By Trust F1, F3, F10
transaction BIAF Warrants (right to buy) Purchase +16.3K 16.3K Aug 31, 2022 Common Stock 16.3K $7.35 By Trust F1, F3, F11
transaction BIAF Non-tradeable Warrants (right to buy) Purchase +16.3K 16.3K Aug 31, 2022 Common Stock 16.3K $7.66 By Trust F1, F3, F11
transaction BIAF Warrants (right to buy) Award +12.2K 12.2K Sep 6, 2022 Common Stock 12.2K $6.13 Direct F1, F12
transaction BIAF Warrants (right to buy) Purchase +408K 408K Sep 6, 2022 Common Stock 408K $6.13 By Trust F1, F3, F13
transaction BIAF Warrants (right to buy) Award +4.9K 4.9K Jul 20, 2022 Common Stock 4.9K $5.25 Direct F1, F14
transaction BIAF Warrants (right to buy) Purchase +163K 163K Jul 20, 2022 Common Stock 163K $5.25 By Trust F1, F3, F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
F2 These securities are owned directly by Mr. Gary Rubin ("Mr. Rubin"), a director of the Issuer.
F3 These securities are owned directly by the Harvey Sandler Revocable Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Mr. Rubin as co-trustee of the Trust. Mr. Rubin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4 In connection with the closing of the Issuer's IPO (the "IPO Closing") on September 6, 2022, the $66,682.86 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a "Note"), dated December 21, 2018, automatically converted into 15,876 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
F5 In connection with the IPO Closing on September 6, 2022, the $1,120,773.84 of outstanding principal and accrued but unpaid interest of this Note, dated December 21, 2018, automatically converted into 266,850 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
F6 In connection with the IPO Closing on September 6, 2022, the $160,808.22 of outstanding principal and accrued but unpaid interest of this Note, dated February 7, 2019, automatically converted into 38,287 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
F7 In connection with the IPO Closing on September 6, 2022, the $394,048 of outstanding principal and accrued but unpaid interest of this Note, dated April 18, 2019, automatically converted into 93,821 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
F8 In connection with the IPO Closing on September 6, 2022, the $268,626.30 of outstanding principal and accrued but unpaid interest of this Note, dated July 26, 2019, automatically converted into 63,958 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
F9 In connection with the IPO Closing on September 6, 2022, the $246,027.40 of outstanding principal and accrued but unpaid interest of this Note, dated October 22, 2019, automatically converted into 58,577 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
F10 In connection with the IPO Closing on September 6, 2022, the 1,612,163 shares of Series A Preferred Stock owned by the Trust automatically converted at the then-effective 1-for-7 conversion rate into 230,309 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date.
F11 The reported securities are included within 16,326 Units purchased by the Trust for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.
F12 Represents a right to purchase 12,241 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Rubin on August 25, 2021 as consideration for his agreement to enter into an amendment to that certain Secured Convertible Note Purchase Agreement, dated December 21, 2018, as amended (the "Note Purchase Agreement") to extend the maturity date of the Note issued to him under the Note Purchase Agreement from December 31, 2021 to May 31, 2022.
F13 Represents a right to purchase an aggregate of 408,125 shares of Common Stock underlying five warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to the Trust on August 25, 2021 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to the Trust under the Note Purchase Agreement from December 31, 2021 to May 31, 2022.
F14 Represents a right to purchase 4,896 shares of Common Stock underlying a warrant at an exercise price of $5.25 per share. The warrant was issued to Mr. Rubin on July 20, 2022 as consideration for his agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Note issued to him under the Note Purchase Agreement from August 31, 2022 to October 31, 2022.
F15 Represents a right to purchase an aggregate of 163,248 shares of Common Stock underlying five warrants at an exercise price of $5.25 per share. The warrants were issued to the Trust on July 20, 2022 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to the Trust under the Note Purchase Agreement from August 31, 2022 to October 31, 2022.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Gary D. Rubin) Exhibit 24.2: Power of Attorney (Harvey Sandler Revocable Trust)